When CMS shared a list of cardiologists being targeted with a brand new payment model, the American College of Cardiology identified a long list of apparent mistakes.

The Class II recall includes nearly 935,000 bottles of a medication that has been on the market for years. 

The groups hope to standardize heart failure terminology and ensure everyone is on the same page when discussing this complex condition. 

The daily polypill was also associated with improved drug adherence, according to new research out of UT Southwestern.

The long-lasting implant could help patients benefit from semaglutide therapy without needing to take the drug on a daily basis. 

Eplontersen, a once-monthly ATTR-CM medication from AstraZeneca and Ionis Pharmaceuticals, failed to meet the primary endpoint of a new placebo-controlled analysis. The companies are still reviewing the final data, which will be presented to the public in August. 

No drugs are currently approved by the FDA for the treatment of symptomatic, nonobstructive HCM. Could oral therapy ninerafaxstat be the first?